Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Delafloxacin - Melinta Therapeutics/Wakunaga Pharmaceutical

Drug Profile

Delafloxacin - Melinta Therapeutics/Wakunaga Pharmaceutical

Alternative Names: ABT-492; Baxdela; Quofenix; RX-3341; RX-3341-83; WQ-3034

Latest Information Update: 12 Mar 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Wakunaga Pharmaceutical
  • Developer Abbott Laboratories; Eurofarma; Melinta Therapeutics; Menarini
  • Class Anti-infectives; Antibacterials; Azetidines; Fluoroquinolones; Pyridines; Small molecules
  • Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Skin and soft tissue infections
  • Registered Community-acquired pneumonia
  • No development reported Urinary tract infections
  • Discontinued Acute exacerbations of chronic bronchitis; Anthrax; Gonorrhoea; Intra-abdominal infections

Most Recent Events

  • 26 Feb 2021 Committee for Medicinal Products for Human Use recommends approval for indication extension of delafloxacin for Community acquired pneumonia in European Union
  • 05 Nov 2020 Menarini terminates a phase IIIb DRESS trial for Skin and soft tissue infections in Austria, Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Italy, Latvia, Poland, Slovenia, Spain and in the UK due to COVID -19 pandemic (IV) (PO) (EudraCT2018-001082-17) (NCT04042077)
  • 22 Jun 2020 Antimicrobial data from a phase III trial in Community-acquired pneumonia presented at the ASM Microbe (ASMM-2020)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top